In the ensuing months, the two companies have published detailed, promising animal studies of their immunotherapies, including preclinical efficacy studies in animal models of
human synucleinopathies.
AFF 1: Preclinical Efficacy Data AFF 1 was then tested for preclinical efficacy in two models of
human synucleinopathy: mThy1 - AS mice, and also PDGF - AS mice expressing WT human AS under the PDGF - β promoter — a model with closer neuropathological and metabolic resemblance to LBD than PD.